Genetic Susceptibility and Risk of Second Cancers in Patients Who Have Undergone Stem Cell Transp… (NCT00949052) | Clinical Trial Compass
TerminatedNot Applicable
Genetic Susceptibility and Risk of Second Cancers in Patients Who Have Undergone Stem Cell Transplant for Cancer
Stopped: Low accrual
United States1,000 participantsStarted 2009-01
Plain-language summary
RATIONALE: Identifying genes that increase a person's susceptibility to second cancers may help the study of cancer treatment.
PURPOSE: This study is looking at genetic susceptibility and risk of second cancers in patients who have undergone stem cell transplant for cancer.
Who can participate
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
CASES are those who:
* Survived at least 100 days post-hematopoietic stem cell transplantation (HSCT).
* Developed an SMN after that time point.
* And received TBI as part of the preparative regimen.
CONTROLS are randomly selected:
* In a 4:1 ratio to cases from the same cohort of 100 day + survivors of HSCT who received TBI.
* Controls will be matched to the cases by race and primary diagnosis.
* In addition, they must have survived for at least the elapsed time between the case's HSCT and the secondary cancer, without development of an SMN.
* We are matching on primary diagnosis, as genotype or radiation sensitivity may predispose to specific primary cancers, as well as the SMNs.
* We are matching on race, as allele frequencies vary widely across ethnic groups.
Exclusion Criteria:
* Did not survive at least 100 days post-hematopoietic stem cell transplantation (HSCT).
* Did not develop an SMN after that time point.
* Did not receive TBI as part of the preparative regimen.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Genetic susceptibility to the carcinogenic effects of radiotherapy, tobacco, and UV light and risk of second malignant neoplasms (SMN)